Should aspirin (including low‑dose aspirin for cardiovascular prophylaxis) be continued in a patient with dengue fever?

Aspirin Should Be Discontinued in Patients with Dengue Fever

Aspirin (including low-dose aspirin for cardiovascular prophylaxis) should be stopped in patients with dengue fever due to the significant risk of bleeding complications, particularly given dengue's characteristic thrombocytopenia and coagulopathy. 1, 2

Rationale for Discontinuation

Bleeding Risk in Dengue

Dengue fever causes thrombocytopenia, impaired platelet function, and coagulopathy 3, 4. The FDA drug label explicitly warns that aspirin increases the risk of stomach bleeding, particularly in patients who:

• Take blood thinning medications
• Have bleeding problems
• Are age 60 or older 1

Aspirin must not be used in dengue because it promotes bleeding and acidosis 2. This contraindication applies to all NSAIDs with antiplatelet effects, though aspirin carries particular concern.

Disease Progression Considerations

Dengue follows a triphasic course (febrile phase, critical phase, recovery phase), with the critical phase occurring around days 3-7 when fever subsides 3, 5. During this period, plasma leakage and bleeding complications are most likely to occur. Severe dengue with hemorrhagic manifestations carries 1-5% mortality 5.

Special Circumstance: Patients on Aspirin for Cardiovascular Disease

This creates a clinical dilemma requiring careful risk stratification:

When Aspirin Was for Primary Prevention

• Discontinue aspirin - The bleeding risk clearly outweighs cardiovascular benefit during acute dengue
• Primary prevention aspirin is only indicated for 10-year ASCVD risk >10% 6
• Temporary discontinuation (typically 7-14 days during acute illness) poses minimal cardiovascular risk

When Aspirin Was for Secondary Prevention (Prior MI, Stroke, Stents)

The decision becomes more nuanced but discontinuation is generally still recommended:

• A retrospective study of 262 dengue patients found that temporary discontinuation of antiplatelet therapy did not result in higher rates of major adverse cardiac and cerebrovascular events (MACCE) or mortality 7
• For patients with recent coronary stents, the risk must be balanced against stent thrombosis risk 4
  • Drug-eluting stents <12 months: Highest risk scenario - consider continuing aspirin alone if patient is past critical bleeding phase, but discontinue P2Y12 inhibitor
  • Bare metal stents <1 month: Very high risk - similar approach
  • Older stents: Safer to discontinue temporarily

Practical Management Algorithm

For patients on aspirin presenting with dengue:

1. Assess dengue severity and platelet count

   • Platelet count <50,000/μL: Discontinue all antiplatelet agents
   • Platelet count 50,000-100,000/μL with warning signs: Discontinue
   • Platelet count >100,000/μL, no warning signs, mild disease: Consider continuation only if recent high-risk stent

2. Assess cardiovascular risk

   • Primary prevention: Discontinue immediately
   • Secondary prevention without recent stent (>12 months): Discontinue
   • Recent stent (<12 months): Individualized decision based on stent type and dengue severity

3. Monitor closely during critical phase (days 3-7)

   • Daily platelet counts
   • Watch for warning signs: abdominal pain, persistent vomiting, bleeding, lethargy
   • Hematocrit monitoring for plasma leakage

4. Resume aspirin after recovery

   • When platelet count >100,000/μL and stable
   • After critical phase has passed (typically day 7-10)
   • No active bleeding

Evidence Quality and Gaps

The evidence supporting aspirin discontinuation comes primarily from:

• FDA drug labeling warnings about bleeding risk 1
• Expert consensus and observational data 3, 2
• One retrospective cohort study showing safety of discontinuation 7

No randomized controlled trials exist comparing continuation versus discontinuation of aspirin in dengue patients. However, the biological plausibility of increased bleeding risk combined with observational safety data for discontinuation supports this recommendation.

Common Pitfalls to Avoid

• Don't substitute with other NSAIDs - All NSAIDs are contraindicated, not just aspirin 8, 2
• Don't use acetaminophen excessively - While recommended for fever, dengue can cause hepatitis, and acetaminophen carries hepatotoxicity risk 8
• Don't forget to restart aspirin - Patients with true secondary prevention indications need aspirin resumed after recovery 9
• Don't confuse with post-dengue thrombocytosis - Reactive thrombocytosis can occur after recovery; this is a different scenario where aspirin may be indicated 10

Alternative Fever Management

Use acetaminophen (paracetamol) for fever and pain management, though monitor liver function given dengue's hepatotropism 8, 5. Recent data suggest low-dose ibuprofen may be safe in non-severe dengue, but this remains controversial and is not standard of care 11.